116622-90-3

Basic information

• Product Name: (2,6-DIFLUORO-PHENYL)-ACETYL CHLORIDE
• Synonyms: (2,6-DIFLUORO-PHENYL)-ACETYL CHLORIDE
• CAS NO: 116622-90-3
• Molecular Formula: C₈H₅ClF₂O
• Molecular Weight: 190.57
• Mol File: 116622-90-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2,6-DIFLUORO-PHENYL)-ACETYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (2,6-DIFLUORO-PHENYL)-ACETYL CHLORIDE(116622-90-3)
• EPA Substance Registry System: (2,6-DIFLUORO-PHENYL)-ACETYL CHLORIDE(116622-90-3)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 116622-90-3(Hazardous Substances Data)

Usage

General Description

(2,6-DIFLUORO-PHENYL)-ACETYL CHLORIDE is a chemical compound with the molecular formula C8H5ClF2O. It is an acetyl chloride derivative of 2,6-difluorophenyl, which is commonly used in organic synthesis as a reagent for the acylation of alcohols, amines, and phenols. (2,6-DIFLUORO-PHENYL)-ACETYL CHLORIDE is a colorless to light yellow liquid with a pungent odor, and it is highly reactive and corrosive, making it important to handle with caution. Its reactivity also makes it useful in the pharmaceutical industry for the production of various drugs and pharmaceutical intermediates. Additionally, it can be used in the synthesis of insecticides and herbicides as well.

Upstream product

• 515-96-8 oxalamic acid hydrazide 
• 85068-28-6 2,6-difluorophenylacetic acid 

Downstream Products

• 1045820-62-9 1-bromo-3-(2,6-difluorophenyl)propan-2-one 
• 221121-46-6 ethyl 4-(2,6-difluorophenyl)-3-oxobutanoate 

Relevant articles and documents

Synthesis of 1,3,4-trisubstituted pyrrolidines as meropenem adjuvants targeting New Delhi metallo-β-lactamase

The effective strategies to neutralize the New Delhi metallo-β-lactamase (NDM-1) activity offer unique opportunities to combination therapy because NDM-1 inactivates all classes of carbapenem antibiotics, which are widely regarded as the last resort of drugs for treating serious bacterial infections. Here we describe the efficient construction of a series of trans-1,3,4-trisubstituted pyrrolidines via boric acid-catalyzed 1,3-dipolar cycloaddition of N-benzylazomethine ylide with methyl ferulate for the biological evaluation of their cytotoxicity and synergistic activity in combination with meropenem towards NDM-1 positive carbapenem-resistant Enterobacteriaceae (CRE). The cell-based screens generated one promising hit, namely compound 10e, which exhibited low cytotoxicity (IC50 > 128 μM), moderate NDM-1 enzyme inhibition (IC50 = 51 μM), and potent synergistic activity against a panel of clinically isolated NDM-1 positive CRE with fractional inhibitory concentration indexes ranging from 0.01 to 0.25. Structure-activity relationship studies revealed that the zinc-chelating moiety of 2-(bis(pyridin-2-ylmethyl)-amino)acetyl group of compound 10e plays a pivotal role for potent activity. Regarding the inhibition mechanism, a series of biochemical assays revealed that compound 10e may inactivate NDM-1 activity by displacing both zinc ions from the active site of the enzyme. Altogether, our studies indicate that compound 10e represents an important pyrrolidine-type scaffold targeting NDM-1, providing a promising starting point to be further developed as carbapenem antibiotic adjuvants. This journal is

Structural insight into the optimization of ethyl 5-hydroxybenzo[g]indol-3-carboxylates and their bioisosteric analogues as 5-LO/m-PGES-1 dual inhibitors able to suppress inflammation

The release of pro-inflammatory mediators, such as prostaglandines (PGs) and leukotrienes (LTs), arising from the arachidonic acid (AA) cascade, play a crucial role in initiating, maintaining, and regulating inflammatory processes. New dual inhibitors of 5-lipoxygenase (5-LO) and microsomal prostaglandin E2 synthase-1 (mPGES-1), that block, at the same time, the formation of PGE2 and LTs, are currently emerged as a highly interesting drug candidates for better pharmacotherapie of inflammation-related disorders. Following our previous studies, we here performed a detailed structure-based design of benzo[g]indol-3-carboxylate derivatives, disclosing several new key factors that affect both enzyme activity. Ethyl 2-(3,4-dichlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate (4b, RAF-01) and ethyl 2-(3,4-dichlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate (7h, RAF-02) emerged as the most active compounds of the series. Additionally, together with selected structure based analogues, both derivatives displayed significant in vivo anti-inflammatory properties. In conclusion, modeling and experimental studies lead to the discovery of new candidate compounds prone to further developments as multi-target inhibitors of the inflammatory pathway.

SERINE RACEMASE INHIBITOR

A novel serine racemase inhibitor exhibits sufficient activity and specificity. The serine racemase inhibitor includes one or more compounds selected from compounds respectively represented by the following general formulas [MM_1], [DR_1], [DR'_1], [LW_1], and [ED_1] as an active ingredient.